Raymond James analyst Steven Seedhouse raised the firm’s price target on Apellis (APLS) to $110 from $106 and keeps a Strong Buy rating on the shares. Updates provided at the one-day-one-track Angiogenesis 2024 meeting and details provided on Astellas’ (ALPMF) call on Monday are broadly positive for Syfovre and Apellis, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis price target raised to $79 from $75 at Oppenheimer
- Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
- Apellis announces negative CHMP opinion for pegcetacoplan for GA
- Apellis price target raised to $75 from $70 at Needham
- Apellis price target raised to $81 from $71 at Baird